Lonza Group
LONN.SW Large CapHealthcare · Diagnostics & Research
Updated: Aug 20, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segm
Lonza Group Stock at a Glance
Lonza Group (LONN.SW) is currently trading at CHF 585.80 with a market capitalization of $40.9B. The trailing P/E ratio stands at 37.89x, with a forward P/E of 26.65x. The 52-week range spans from CHF 454.60 to CHF 591.00; the current price is 0.9% below the yearly high. Year-over-year revenue growth stands at +11.2%.
💰 Dividend
Lonza Group pays an annual dividend of CHF 5.00 per share, representing a yield of 0.85%. The payout ratio stands at 32.28%.
📊 Analyst Rating
23 analysts rate Lonza Group (LONN.SW) on consensus: Buy. The average price target is CHF 681.13, implying +16.27% from the current price. Analyst price targets range from CHF 550.00 to CHF 835.00.
Lonza Group: The Investment Case in Detail
Lonza Group (LONN.SW) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Revenue is growing at a healthy 11.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 39.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 16.27% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valuation in Context
The PEG ratio at 1.26 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
What to Watch Next
- The forward P/E of 26.65x is meaningfully below the trailing 37.89x — analysts expect earnings to step up; the next earnings release is the test.
- The share is trading at 96.2% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Buy
- –Currently unprofitable
- –Currently flagged as overvalued
- –Negative free cash flow
- –Price near 52-week high — limited upside cushion
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Lonza 2026: GLP-1 Manufacturing Bottleneck + Vacaville Acquisition Reposition This Swiss CDMO for the Biologics Decade
The Real Story
Lonza Group is the world's largest contract development and manufacturing organisation (CDMO) for biologics, serving Big Pharma and biotech clients with everything from clinical-trial supply to commercial-scale production of monoclonal antibodies, gene therapies, and increasingly GLP-1 peptide drugs (Wegovy, Mounjaro, Zepbound). The 2024-2025 narrative was a turbulent transition: Lonza divested its lower-margin Capsules & Health Ingredients division in early 2025, simultaneously absorbing the $1.2 billion Vacaville (California) biologics facility purchased from Genentech — the largest single-site mammalian-cell production facility in the world. The 2026 story is the integration win. Vacaville comes online with multi-year client commitments already booked, GLP-1 capacity sells out roughly 18 months ahead of demand, and gene-therapy CDMO services remain the highest-margin sub-segment with limited credible competition. CEO Wolfgang Wienand has guided FY2026 organic revenue growth of 12-15%, with core EBITDA margin recovering to 30%+ as Vacaville absorption costs run off. The strategic narrative has flipped from «execution turnaround» to «growth compounder with manufacturing scarcity premium».
What Smart Money Thinks
The smart-money base in Lonza is a mix of Swiss long-only legacy (UBS, Pictet, Bellevue), specialist pharma/healthcare funds (BB Biotech, RTW Investments), and global high-quality compounders (Fundsmith, Lindsell Train). Terry Smith's Fundsmith has been a top-15 holder since 2022 and added through the 2024 selloff — an unusually high-conviction signal given his concentration. There has been no major activist pressure, partly because the Swiss-board governance structure makes activism mechanically harder, but also because the Vacaville-plus-GLP-1 thesis has been broadly accepted by the long-only universe. On the short side, hedge funds focused on biologic-manufacturing oversupply risk have been bearish — Samsung Biologics, WuXi Biologics, and incumbent in-house capacity at Roche/Genentech all could in theory soften pricing. So far this thesis has not played out.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Wegovy and Zepbound combined ran at peptide-API capacity ceilings throughout 2024-2025. Novo Nordisk and Eli Lilly have both signed multi-year contracts with Lonza for capacity expansion, and Lonza's Visp (Switzerland) peptide facility is on a 24-month order backlog. As long as GLP-1 demand keeps exceeding global capacity, Lonza captures premium pricing with low execution risk — the molecules are well-characterised and the manufacturing process is established.
The $1.2 billion Vacaville facility from Genentech comes with 330,000 litres of mammalian-cell capacity — roughly 15% of global commercial-scale biologics capacity in a single site. Multi-year contracts with two undisclosed Big Pharma clients were signed before closing, providing 70%+ utilization from day one. The site adds approximately $600M of annual revenue at 35% gross margin from 2027 onwards.
Lonza's Houston facility is one of three commercial-scale gene-therapy CDMOs globally, alongside Catalent (now Novo Nordisk owned) and FUJIFILM Diosynth. The sub-segment grew 28% in 2025 and is expected to compound at 25%+ through 2028. Pricing power remains exceptional because gene therapy manufacturing requires single-source qualification — clients cannot easily switch providers mid-program.
📉 The 3 Real Bear Points
The Genentech Vacaville site was operated for 30+ years under Roche standards. Successfully transitioning quality systems, validating multi-product runs, and re-qualifying processes for new clients takes 12-18 months. Any FDA inspection deficiency during the transition would meaningfully impact ramp economics and could trigger client penalties.
Lonza's top 5 clients account for roughly 35% of revenue, with Novo Nordisk and Eli Lilly representing 18% combined via GLP-1 contracts. If either party were to materially in-source manufacturing or shift to a different CDMO, the impact would be immediately visible in quarterly results. Lonza is exposed to single-client decisions that are largely outside its control.
2026 capex is guided at CHF 1.0-1.2 billion, exceeding 16% of revenue. While this funds the Vacaville integration and additional peptide-API capacity, free cash flow will be roughly CHF 800M in 2026 versus EBITDA of CHF 2.4 billion — a working-capital and capex drag that limits short-term shareholder returns.
Valuation in Context
Lonza trades at 19.5× forward earnings and 13× EV/EBITDA — both meaningful premiums to general industrials but discounts to peers Catalent (pre-acquisition 22×) and Samsung Biologics (28×). The valuation embeds successful Vacaville integration and continued GLP-1 capacity scarcity. The FCF yield is roughly 2.5% — modest now, but expected to expand to 5%+ by 2028 as capex normalises. Bull case (Vacaville ramps smoothly, GLP-1 contracts extended, gene-therapy margins hold): CHF 720. Base case (steady execution, no major surprises): CHF 595. Bear case (Vacaville delay + GLP-1 in-sourcing + competitive capacity additions): CHF 420.
🗓️ Next 3 Catalyst Dates
- July 24, 2026: H1/2026 results — first half with material Vacaville contribution; watch for capacity utilization metrics.
- October 2026: Q3/2026 trading update — visibility into GLP-1 contract renewals for 2027-2028.
- February 2027: FY2026 full results + 2027-2030 mid-term guidance refresh — expected confirmation of 30%+ EBITDA margin trajectory.
💬 Daniel's Take
Lonza is one of my higher-conviction European holdings (3% portfolio weight). The thesis is simple: biologic manufacturing capacity is structurally scarce, gene therapy is just beginning its commercial decade, and GLP-1 demand is going to compound for at least another 3-5 years. Owning the most credible neutral manufacturing partner with the largest installed capacity is the asset-light way to play biotech innovation without picking individual drug winners. Where I'd be cautious for a new entry: the multi-year ramp risk on Vacaville is real, and CHF 600-plus is not a cheap absolute valuation. Wait for a 10-15% pullback before adding, or scale in over six months. But the 2026-2028 growth trajectory is among the most visible in European large-caps.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Lonza Group?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news